MedTrace Logo

LFD of Aspergillus Antigen in Paediatrics

NCT05569824 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2022-10-13

No results posted yet for this study

Summary

Many children and young people are at risk of invasive fungal disease (IFD), such as those who have had a haematopoietic stem cell transplants, those with an immune deficiency or those who are prescribed immunosuppressive drugs, for example, corticosteroids. One type of mould that causes invasive fungal disease is called Aspergillus. There is currently no quick test which can tell us if someone has an invasive fungal disease caused by Aspergillus called Aspergillosis. It is a difficult condition to diagnose and the results from the tests that are involved take days or weeks to come back. These tests including a few different blood tests, a scan of the lungs (CT scans) and taking fluid from inside the lungs/airway.

A new test for Aspergillosis is the lateral flow device (LFD) assay. This is a rapid test which gives a result within minutes. It involves testing a sample of the fluid from the lungs/airway. This fluid can be obtained as part of the routine investigations for Aspergillosis. It has been shown to be a good and safe test in adults but the investigators do not know if it will be a valuable test in children and young people yet. The purpose of this study is to determine whether the LFD test can effectively diagnose Aspergillosis in children and young people.

Conditions

  • Invasive Pulmonary Aspergillosis
  • Invasive Fungal Disease

Interventions

DIAGNOSTIC_TEST

Lateral-flow Device

An additional amount of 0.1-0.2 ml (2-4 drops) of bronco-alveolar lavage (BAL) fluid will be collected during the bronchoscopy which is carried out as part of the standard of care. The LFD test will be carried out on the BAL fluid collected.

Sponsors & Collaborators

  • University of Exeter

    collaborator OTHER

  • University College, London

    collaborator OTHER

  • St George's, University of London

    collaborator OTHER

  • Fungal Infection Trust

    collaborator UNKNOWN

  • St George's University Hospitals NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Laura Ferreras-Antolin · St George's University Hospitals NHS Foundation Trust

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-10
Primary Completion
2024-01-19
Completion
2024-04-29

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05569824 on ClinicalTrials.gov